Artivion, Inc. (NYSE:AORT) Holdings Reduced by Kennedy Capital Management LLC

Kennedy Capital Management LLC lessened its holdings in shares of Artivion, Inc. (NYSE:AORT) by 75.6% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 136,617 shares of the company’s stock after selling 422,352 shares during the quarter. Kennedy Capital Management LLC’s holdings in Artivion were worth $2,891,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. GAMMA Investing LLC raised its stake in Artivion by 38.6% during the 1st quarter. GAMMA Investing LLC now owns 1,814 shares of the company’s stock valued at $38,000 after acquiring an additional 505 shares in the last quarter. Texas Permanent School Fund Corp lifted its position in Artivion by 2.0% in the first quarter. Texas Permanent School Fund Corp now owns 34,129 shares of the company’s stock worth $722,000 after purchasing an additional 677 shares during the period. SG Americas Securities LLC grew its holdings in Artivion by 7.8% during the fourth quarter. SG Americas Securities LLC now owns 13,393 shares of the company’s stock worth $239,000 after acquiring an additional 968 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Artivion by 5.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,690 shares of the company’s stock valued at $713,000 after acquiring an additional 1,634 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Artivion by 25.3% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,430 shares of the company’s stock valued at $186,000 after buying an additional 2,108 shares during the period. 86.37% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on AORT. Stifel Nicolaus lifted their target price on shares of Artivion from $22.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, May 7th. Needham & Company LLC raised their price target on shares of Artivion from $25.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Finally, Lake Street Capital lifted their price target on shares of Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd.

Artivion Trading Down 0.1 %

Shares of AORT stock traded down $0.03 on Wednesday, reaching $27.20. 30,844 shares of the stock were exchanged, compared to its average volume of 221,589. The company has a debt-to-equity ratio of 1.07, a current ratio of 6.04 and a quick ratio of 4.26. Artivion, Inc. has a one year low of $12.16 and a one year high of $29.24. The stock has a market cap of $1.13 billion, a PE ratio of -113.46 and a beta of 1.75. The stock has a 50 day moving average price of $25.04 and a 200 day moving average price of $21.72.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, May 6th. The company reported $0.06 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.04. Artivion had a positive return on equity of 3.64% and a negative net margin of 2.61%. The business had revenue of $97.43 million during the quarter, compared to analysts’ expectations of $92.30 million. Equities research analysts forecast that Artivion, Inc. will post 0.24 EPS for the current fiscal year.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.